Open AccessSofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies
Author(s) -
Ronald Nahass,
Eric Lawitz,
Ira M. Jacobson,
Paul Y. Kwo,
Mindie Ngyuyen,
Jenny C. Yang,
Luisa M. Stamm,
Sophia Lu,
Hadas D. Sobol,
Sarjita Naik,
Joe Llewellyn,
Diana M. Brainard,
John G. McHutchison,
Michael P. Curry,
Kris V. Kowdley,
Nancy Reau,
Edward Gane
Publication year - 2016
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofw194.143
Subject(s) - medicine , sofosbuvir , hepatitis c virus , genotype , virology , hepatitis c , virus , gastroenterology , ribavirin , biology , gene , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom